Dr. Rania Ibrahim Hassan is a seasoned pharmaceutical professional with over 20 years of experience in Good Clinical Practice (GCP), Good Pharmacovigilance Practice (GPvP), and Regulatory Affairs. Passionate about advancing global health, Dr. Ibrahim has been instrumental in achieving WHO Qualification in the vaccine scope for the Egyptian Regulatory Authority since 2006.
With a strong foundation in Quality Assurance, Quality Control, and Technical Methodology, Dr. Ibrahim has successfully led teams to reduce regulatory compliance issues through improved quality systems. Her expertise in quality system management, performance improvement, and validation has been instrumental in optimizing operational efficiency and ensuring product quality.
As a former Operation Manager / Pharmaceutical Facility Manager / QPPV at the Egyptian Company for Advanced Pharmaceuticals (ECAP), Dr. Ibrahim oversaw all technical aspects of product development and manufacturing, ensuring adherence to GMP standards and regulatory compliance. She also played a key role in setting annual production plans, resulting in a 15% increase in production output.
Dr. Ibrahim has held leadership positions at the Egyptian Drug Authority, including General Manager of the General Administration of Clinical Trials at CA for Biological and Innovative Products and Clinical Trials – Bio Inn. In this role, she successfully led the implementation of the WHO Global Benchmarking Tool Maturity Level 3 in the vaccine scope for the Egyptian Drug Authority in March 2022, resulting in a significant improvement in the efficiency of clinical trial review processes.
Dr. Ibrahim's commitment to excellence and innovation is evident in her role as a lecturer at Kings College London, where she shares her expertise in Drug Regulatory Affairs with aspiring professionals. Her unique blend of technical knowledge, leadership skills, and passion for patient safety makes her a valuable asset to any organization.
